Pfizer Reaps Early Rewards from Seagen Deal with 20% Oncology Surge (PFE Q1 2026 Earnings Call)
Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.
Pfizer delivered a highly constructive first quarter in 2026, punctuated by strong execution across its strategic acquisitions and a significant legal victory that dramatically improves its long-term growth profile. The pharmaceutical giant is successfully transitioning its revenue base away from COVID-19 products, achieving robust operational growth in its underlying business. Management highlighted that early returns from major acquisitions, particularly Seagen and Biohaven, are providing the necessary momentum to offset upcoming patent expirations later in the decade.
Strategic Acquisitions Drive Underlying Business Growth
Pfizer reported total first-quarter revenues of $14.5 billion, representing a 2% operational increase despite the expected decline in pandemic-related sales. Crucially, excluding the COVID-19 franchise, the underlying business achieved a robust 7% operational growth rate, reflecting strong demand across primary and specialty care. A major catalyst was the company's recently launched and acquired products, which generated $3.1 billion in the quarter and grew by 22%, validating the company's aggressive business development strategy.
Oncology and Migraine Portfolios Exceed Expectations
The company's deep investments in specialized therapeutic areas are yielding substantial commercial dividends. The oncology portfolio, bolstered by the Seagen acquisition, posted a 20% year-over-year operational revenue increase as Pfizer successfully integrated the new commercial teams. In the migraine space, Nurtec experienced a staggering 41% operational growth, reflecting robust patient demand for acute and preventive treatments. Furthermore, targeted cost controls led to a 5% decrease in adjusted SI&A expenses, helping secure a highly efficient 38% adjusted operating margin.
Legal Victories Reshape Long-Term Financial Profile
Two major legal developments occurred during the quarter that materially alter Pfizer's future cash flow outlook and dividend security. A patent settlement regarding the cardiovascular drug Vyndamax effectively extends its exclusivity to mid-2031, which drastically reduces the company's anticipated loss of exclusivity impact. This agreement gives management high confidence in achieving a high single-digit revenue CAGR over a 5-year period starting in 2029. Consequently, adjusted diluted earnings per share reached $0.75, easily beating internal expectations.
Advancing the Next Generation of Transformative Medicines
Pfizer's R&D engine remains heavily focused on high-impact areas, directing investments toward oncology and metabolic diseases. In oncology, the combination of Padcev and pembrolizumab demonstrated a nearly 50% reduction in the risk of recurrence or death for muscle-invasive bladder cancer, positioning it as a potential new standard of care. Meanwhile, the company is aggressively pursuing the obesity market, aiming to advance 10 Phase III studies this year. Management ultimately reaffirmed its full-year guidance, expecting total revenues between $59.5 billion and $62.5 billion.